ERA®

Endometrial Receptivity Analysis **by Igenomix**

If you have had implantation failures, we can help you

Patented since 2009



What is the endometrium?

The interior of the uterus is lined with a tissue called endometrium, which is prepared each month for the arrival of an embryo and is the place where the embryo implants and resides. When this does not occur, menstruation begins and the endometrial lining is shed.

Endometrial receptivity

Sometimes embryo implantation in the endometrium does not develop successfully. This failure can occur for different reasons. A particularly important factor is endometrial receptivity. The endometrium is receptive when it is ready for embryo implantation to occur. This period of receptivity is called the window of implantation.



Problems with the endometrial lining are one of the leading causes of infertility in women

What is the ERA test?

ERA is the first diagnostic test developed to identify the window of implantation with proven and published clinical efficiency.

ERA is a diagnostic method developed and patented by Igenomix R&D department since 2009, after more than 10 years of research. ERA allows us to evaluate the endometrial receptivity status of a woman.

This biopsy is quickly and easily taken by physician in their office.

In our laboratory, the sample is sequenced by next generation sequencing to obtain the expression of 248 genes involved in the endometrial receptivity. An in-house designed computational predictor analyzes the data obtained, classifying the endometrium as Receptive or Non-Receptive.

If receptive, the window of implantation (WOI) is defined at the time when the sample was taken. Meaning **the embryo is capable of implantation in the uterus during this period of time.**

A state of non receptivity means that the window of implantation is displaced.

The ERA predictor will indicate your optimal window of implantation. This will allow for personalized embryo transfer.



What are the advantages?

Pregnancy rate using the ERA test in patients starting assisted reproductive treatments is 72.5%. (Simon et al., ASRM, 2019)*

How can I access ERA?

Ask your physician for further information.

If you have any questions, contact us at: www.igenomix.eu

Igenomix Publications: https://www.igenomix.es/test/era-analisis-receptividad-endometrial

*Simon et al. ASRM Oral communication 2019; 112(3): Supp e56-e57



www.igenomix.eu